Transfer-RNA-derived fragments (tRFs) are a relatively recently discovered class of non-coding RNAs derived from both precursor and mature transfer RNAs (tRNAs). Research on these molecules has been expanding rapidly, revealing their diverse roles in cellular processes, both in normal physiology and in disease states, often via post-transcriptional regulation of target genes. Altered tRFs abundances have been implicated in various conditions, where they may act as either drivers of disease progression or as protective agents. For instance, specific tRFs are associated with increased risk for cancer metastasis, while others may suppress tumor cell proliferation. Despite the growing recognition of tRFs as functional RNAs rather than sequencing noise, this field of study faces numerous challenges. Inconsistent naming conventions and variability in experimental approaches hinder the comparison of findings across studies, limiting our understanding of the common roles and mechanisms of tRFs. This review provides a comprehensive analysis of current literature on the various roles of tRFs in different diseases, particularly focusing on four broad areas: cancer, neurological, cardiovascular, and musculoskeletal disorders. We analyze studies that link specific tRFs to various aspects of human diseases and provide a convenient classification of these studies regarding the depth of the provided evidence. Further, we note gaps in current investigations and consider strategies to address methodological inconsistencies, including validation experiments and unified nomenclature. By consolidating research in this manner, we aim to facilitate comparisons across diverse studies, enhancing our ability to identify functional commonalities and furthering our understanding of the mechanisms by which tRFs act.
Introduction: Antimicrobial resistance is a major and growing concern worldwide. The study aimed to describe the occurrence and characterize the antimicrobial resistance profile of carbapenemase-producing Enterobacterales (CPE) isolated from clinical specimens at a private healthcare center in Lima, Peru, between January 2018 and December 2019. Methodology: A total of 59 bacterial isolates were identified as CPE using the modified carbapenem inactivation method. Bacterial identification and antimicrobial susceptibility testing were performed using the Vitek 2 system, and colistin susceptibility was determined using the compact antimicrobial susceptibility panel. Five carbapenemase encoding genes, including blaNDM, blaIMP, blaVIM, blaOXA-48, and blaKPC, were screened using PCR and lateral flow assay. Also, carbapenemases were screened using the boronic acid- and EDTA-based disk synergy methods. The dynamics of CPE were described every month. Results: Carbapenemase-producing Klebsiella pneumoniae was the most prevalent agent (83.1%), followed by Providencia spp. (6.8%), Escherichia coli (5.1%), Enterobacter cloacae (3.4%), and Citrobacter freundii (1.6%). The isolation of blaNDM-carrying CPE was frequent and increased during the second half of 2019, while blaKPC carriers were detected in the second half of 2018. One CPE carrying blaOXA-48 was detected in June 2019. No other carbapenemase-encoding genes were detected. Conclusions: This report is among the first to document CPE in private health care institutions in Lima, Peru. Results suggest that the emergence and spread of carbapenemases are becoming a latent and growing threat in private healthcare settings.